TherapeuticsMD (STU:29TA) 1-Year Share Buyback Ratio : 0.00% (As of Dec. 2024 )

View and export this data going back to 2014. Start your Free Trial

What is TherapeuticsMD 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. TherapeuticsMD's current 1-Year Share Buyback Ratio was 0.00%.

STU:29TA's 1-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -1.9
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of TherapeuticsMD's 1-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TherapeuticsMD's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

TherapeuticsMD 1-Year Share Buyback Ratio Calculation

TherapeuticsMD's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(11.532	-	11.532)	/	11.532
	=	0.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TherapeuticsMD (STU:29TA) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

TherapeuticsMD 1-Year Share Buyback Ratio Related Terms

TherapeuticsMD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (STU:29TA) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

TXMD:USA

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

TherapeuticsMD Headlines

No Headlines